News Releases

Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 3

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

NEW YORK, Nov. 30, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi, Chief Executive Officer, will present live at VirtualInvestorConferences.com on December 3, 2015.

View investor presentations 24/7 at www.virtualinvestorconferences.com.

DATE: Thursday, December 3, 2015
TIME: 3:15p.m. ET
LINK: http://tinyurl.com/123pre

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Learn more about the event: www.virtualinvestorconferences.com 

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's five marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, for the treatment of pain and fever, Kristalose® (lactulose) for Oral Solution, a prescription laxative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease. Cumberland is developing Hepatoren® (ifetroban) Injection for the treatment of Hepatorenal Syndrome and Boxaban® (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.

About VirtualInvestorConferences.com

VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Logo - http://photos.prnewswire.com/prnh/20151130/291577LOGO

SOURCE Cumberland Pharmaceuticals

For further information: Rebecca Kirkham, Lovell Communications, (615) 297-7766, Rebecca@lovell.com; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, bradley.smith@prnewswire.com